Linklaters has been called in to act for Sanofi-Sythnelabo for the first time on its high-profile E48bn (£33bn) hostile bid for Aventis, after the French giant’s regular counsel was conflicted out.

The bid, which could create the world’s third largest pharmaceutical company, is regarded as a landmark for the French market since hostile bids are extremely rare on the Continent.